Form 4: Pluri Director Maital Shemesh-Rasmussen Receives RSU Grant

Pluri Inc. Director Maital Shemesh-Rasmussen was granted 699 restricted stock units, vesting over three months.

Summary

• Maital Shemesh-Rasmussen, a Director of Pluri Inc., acquired 699 shares of Common Stock.
• These shares were granted as Restricted Stock Units (RSUs) on December 4, 2025, under the Company's 2019 Equity Compensation Plan.
• The RSUs will vest equally on a monthly basis over three months following the grant date.
• Following this transaction, Maital Shemesh-Rasmussen beneficially owns 19,144 shares of Common Stock.

Sentiment

Score: 7

Explanation: A director receiving an equity grant is generally a positive sign of alignment and commitment, though the amount is relatively small in the context of total shares outstanding. It's a routine compensation event.

Positives

• Director Maital Shemesh-Rasmussen received a grant of 699 Restricted Stock Units, aligning her interests with shareholders.
• The grant is part of the Company's 2019 Equity Compensation Plan, indicating ongoing use of equity incentives for directors.

Future Outlook

The vesting schedule of the granted Restricted Stock Units indicates a commitment period for the director over the next three months, aligning future performance with equity ownership.

Management Comments

• The restricted stock units were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan.
• The RSUs vest equally on a monthly basis over three months following the date of grant.

Industry Context

Equity grants to directors are a standard practice across industries, particularly in biotechnology, to incentivize long-term commitment and align leadership interests with shareholder value. This grant is consistent with typical corporate governance practices for public companies.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common form of non-cash compensation in publicly traded biotechnology companies, aligning director interests with shareholders.
• This practice is consistent with compensation strategies observed in peers within the cell therapy or regenerative medicine sectors, such as other companies utilizing equity compensation plans to retain and incentivize board members.
• The vesting schedule over three months, while shorter than typical executive grants, is not uncommon for director compensation, reflecting their oversight role rather than day-to-day operational responsibilities.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially encouraging decisions that benefit long-term stock performance.

Next Steps

• The 699 Restricted Stock Units will vest equally on a monthly basis over the three months following December 4, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to an existing director, which is a standard compensation practice and generally viewed as a positive for aligning interests. However, the transaction itself is not significant enough in scale or nature to warrant a change in investment recommendation. It provides no new material information regarding the company's operational or financial performance that would alter a 'hold' stance.

Keywords

Pluri Inc., PLUR, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Compensation